Bielaxone Injection 1g (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years can receive 1–2 g (potency) of ceftriaxone via intravenous or intramuscular injection once a day. In case of infections caused by pathogens showing moderate susceptibility or severe conditions, the dose may be increased to 4 g (potency) once daily. For intramuscular administration, dissolve in 1% lidocaine hydrochloride solution and inject deeply into the gluteal area. For intravenous administration, slowly inject over 2–4 minutes. During intravenous drip, it should be administered for at least 30 minutes.

Child administration

For newborns (within 14 days of birth), administer 20–50 mg (potency) per Kg of body weight once daily, not exceeding 50 mg (potency). No distinction is made between premature and term infants. For infants and children (from 15 days to 12 years old), the dosage will depend on further details.

This drug should not be mixed with solutions or medications containing calcium. Administering this drug and calcium-containing solutions simultaneously can be dangerous. Particularly, it must not be given to newborns less than 28 days old, as this could lead to precipitation that causes severe problems in the lungs or kidneys. Patients allergic to this drug or who have had hypersensitivity reactions to cephalosporin or penicillin antibiotics should not use this drug. Furthermore, it is safest not to administer it to premature infants or newborns suspected of having bilirubin conjugation disorders. Caution should be exercised when used in patients with poor renal function or a history of drug allergies and in those with allergic predispositions. This drug may cause various side effects such as changes in blood cell counts, diarrhea, rash, liver function abnormalities, and should be reported to medical staff immediately if any unusual symptoms occur. It is important to regularly monitor liver and kidney function and blood tests during administration. Overdose of this medication cannot be removed by hemodialysis or peritoneal dialysis, thus care should be taken to avoid overdose. Symptoms such as dizziness may occur while driving or operating machinery; caution is advised. Pregnant or nursing women should consult a doctor before using this drug, particularly during pregnancy, and it should only be administered carefully when necessary. Dose adjustment and monitoring of the condition are required in children and the elderly. When administering this drug, it is essential to follow medical advice regarding potential interactions with other medications. Any adverse reactions occurring after administration should be reported to healthcare personnel promptly for appropriate measures.

Serious side effects

Hives, severe swelling (edema), cold sweat, pallor, severe allergic reactions, severe rash with high fever, blisters, shedding of skin, pain in mucous membranes of mouth/eyes, severe skin reactions, difficulty breathing or shortness of breath, asthma attacks, respiratory issues accompanied by cough and fever, jaundice (yellowing of skin or eyes), extreme lethargy, liver abnormalities (jaundice), sudden and severe headache, lightning headache.

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This drug must be stored in a sealed container to prevent air or moisture from entering. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve the drug's effectiveness for an extended period.

Appearance

A colorless and transparent vial filled with white to light yellow crystalline powder

Package unit

10 vials/box